Women live longer than men in nearly every society, yet spend approximately 25% more of their lives in poor health. This is not a biological inevitability. It is a systemic design flaw rooted in a male-centric model of science that treated the female body as a deviation from the norm.
"Whose biology is in the model? The answer determines whether the next generation of health systems repeats the errors of the last or builds something genuinely precise."
The Foundational Flaw
From 1977 until 1993, US FDA guidance excluded most women of childbearing potential from phase I and early phase II drug trials. The safety profiles of many modern medicines were established on a heavily male baseline.
In neuroscience, male-only animal studies outnumber female-only by roughly 5.5:1. A 2022 analysis found women still comprise only about 41% of major clinical trial enrollments. The efficacy evidence used to justify reimbursement reflects predominantly male response patterns.
Women experience substantially higher rates of adverse drug reactions - including a 34% higher risk of severe chemotherapy side effects and nearly 50% for immunotherapy.
How Bias Cascades Into AI
Male-centric research → biased guidelines
Biased guidelines → biased clinical documentation
Biased documentation → corrupted EHRs
Corrupted EHRs → biased training data for AI
Biased AI → scaled error at machine speed
Published Evidence of AI Bias
JAMA Network Open: LLM medical advice can differ by patient gender for equivalent clinical scenarios, including differences in escalation intensity.
LSE (2025): Google's Gemma model described men's social care needs as "complex medical history" and "disabled" while using milder language for identical female cases.
Cardiac prediction (2024): Even with balanced training data, false-negative rates were consistently higher for female patients. The AI learned male-pattern symptoms as "signal" and female-pattern symptoms as "noise."
The Economic Toll
McKinsey Health Institute estimates closing the women's health gap could add at least $1 trillion to annual global GDP by 2040 - not from new spending but from reducing systemic waste and unlocking human potential.
The "Double Cost" rule: indirect costs for endometriosis are approximately double the direct costs - healthcare averaging EUR 3,113/woman/year vs. productivity losses EUR 6,298/woman/year.
A survey of over 1,000 employees: 70% lost 1-5 days of productivity in the last month due to women's health issues. 61% had taken time off. Only 10.14% of employees strongly agree their employer provides adequate resources.
Employed women in the US spend approximately $15.4 billion more annually out-of-pocket on healthcare than men (Deloitte). Single women spend 6.8% of income on health insurance vs. 3.9% for single men.
The Opportunity
Scientific: Female biology contains the most successful model of endurance in nature. The uterus regenerates ~400 times over a lifetime. Research into partial reactivation of the second X chromosome has revealed pathways protecting brain myelin - potentially transformative for neurodegenerative disease in all patients.
Technological: The goal is not to de-bias old AI but to build new tools on a corrected, sex-aware data foundation - integrating patient-reported outcomes, life-stage variables, and computable sex-aware clinical rules.
Economic: For nations: untapped growth capital. For insurers: reduced financial volatility. For employers: 74% of women want centralized health resources - companies that provide them will reduce absenteeism and improve retention.
For Decision-Makers
Move from encouraging to mandating sex-disaggregated performance reporting for all new drugs, devices, and algorithms. Switzerland's Human Research Act revision (due end 2026) is the legislative window. Action: Require sex-disaggregated reporting and post-market monitoring for one drug, one device, and one clinical AI workflow in the next regulatory cycle.
Your actuarial models are calibrated to male physiology. Action: Audit one existing risk model for sex-based performance gaps, then reprice or reroute one female-prevalent condition cohort using the corrected model.
Audit all existing health AI models for sex-based performance gaps. The company that produces the first genuinely sex-aware clinical decision support tool will own a market every health system needs to buy. Action: Publish a sex-performance audit for one model, retrain with life-stage features, report before/after error rates.
70% of employees reporting monthly productivity loss are telling you something your HR analytics cannot see. Action: Add women's-health navigation and manager training to one business unit, measure sick leave, retention, and promotion over two review cycles.
Run a Sex-Bias & Deployment Readiness Audit
Show where bias enters the workflow, how to correct it, and what proof point will matter to your buyers or regulators.
Contact FemTechnology →Sources & Evidence Base
All statistics in this analysis are sourced from peer-reviewed literature, government statistical offices, or published claims datasets. Key references:
- Westergaard D et al., Nat Commun 2019 - DOI: 10.1038/s41467-019-08475-9
- Nnoaham KE et al., Fertil Steril 2011 - PMID: 21718982
- Felder S & Werblow A - Swiss MCL: 3.5x disparity
- Gibson-Helm M et al., JCEM 2017 - PCOS: 3.4yr delay, 3+ physicians
- Choy E et al., BMC Health Serv Res 2010 - Fibromyalgia: 5yr delay. DOI: 10.1186/1472-6963-10-102